CCR 20th Anniversary Commentary: Vorinostat-Gateway to Epigenetic Therapy.

Authors

• Wm Kevin Kelly
• Paul Marks
• Victoria M Richon

Publication/Presentation Date

5-15-2015

Abstract

The study by Kelly and colleagues, published in the September 1, 2003, issue of Clinical Cancer Research, established the safety and biologic activity of the first-in-class histone deacetylase inhibitor, vorinostat, which was administered intravenously. Subsequent studies led to the development of oral vorinostat and the regulatory approval of vorinostat for cutaneous T-cell lymphomas, which opened the door for the next generation of inhibitors.

Volume

21

Issue

10

First Page

2198

Last Page

2200

ISSN

1557-3265

Published In/Presented At

Kelly, W. K., Marks, P., & Richon, V. M. (2015). CCR 20th Anniversary Commentary: Vorinostat-Gateway to Epigenetic Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 21(10), 2198–2200. https://doi.org/10.1158/1078-0432.CCR-14-2556

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

25979925

Department(s)

Administration and Leadership

Document Type

Article